

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT		ATTORNEY DOCKET NO.
087405,4	54 0371579	75 SULLIVAN	Ĵ	4249.0002-05

HM11/0624

FINNEGAN HENDERSON FARABOW GARRETT AND DUNNER 1300 I STREET NW WASHINGTON DC 20005-3315

EXA	MINER	
SCHWAL	RON,R	٠.
	· · · · · · · · · · · · · · · · · · ·	
ART UNIT	PAPER NUMBER	
1644	37	


DATE MAILED:

06/24/98

Below is a communication from the EXAMINER in charge of this application COMMISSIONER OF PATENTS AND TRADEMARKS

ADVISORY ACTION

×	ТНЕ	E PERIOD	FOR RESPONSE:					
a)		is extende	ed to run	or continues to run	from the date of the fir	nal rejection		
b)	Ø	expires three months from the date of the final rejection or as of the mailing date of this Advisory Action, whichever is late event however, will the statutory period for the response expire later than six months from the date of the final rejection.						
		The date purposes	on which the response, the of determining the period	he petition , and the fee have be I of extension and the correspon	7 CFR 1.136(a), the proposed responen filed is the date of the response a ding amount of the fee. Any extensi statutory period for response or as a	nd also the date for the on fee pursuant to 37 CFR		
	Арр	pellant's Br	ief is due in accordance	with 37 CFR 1.192(a).	14/98			
Ø	Applicant's Brief is due in accordance with 37 CFR 1.192(a). Applicant's response to the final rejection, filed 5/14/48 has been considered with the following effect, but it is not deemed to place the application in condition for allowance:							
1.		The propo	sed amendments to the o	daim and /or specification will no	t be entered and the final rejection s	tands because:		
 a. There is no convincing showing under 37 CFR 1.116(b) why the proposed amendment is necessary and was not earlier presented. 								
		b. The	y raise new issues that w	ould require further consideratio	n and/or search. (See Note).			
		c. 🔲 The	y raise the issue of new I	matter. (See Note).				
			ey are not deemed to pla seal.	ce the application in better form	for appeal by materially reducing or	simplifying the issues for		
		e. 🗌 The	ey present additional clair	ns without cancelling a correspo	nding number of finally rejected clain	ns.		
						•		
		NOTE: _				 		
		_						
2.			pposed or amended claim	ns would be	allowed if submitted in a separately	filed amendment cancelling		
3.	X	Upon the		osed amendment 🔀 will be en	tered will not be entered and the	status of the claims will		
		Claims all	owed: Nont		·			
			ected to: 40 -47	<u>ጽ</u> ኔ. ዛና-ዛን				
			Januarian					
		Appli	cant's response has over	come the following rejection(s):	ser enclosed	prefixac note		
	_					- the		
4.	<u>z</u>	The affida	evit, exhibit or request for	reconsideration has been consi	dered but does not overcome the rej	(loso note		
5.			wit or exhibit will not be c		s not shown good and sufficent reaso			
	The	proposed	drawing correction	has has not been approve	d by the examiner. M. & C.	el 122/15		
X	Oth	ner 5	というもり		•	RONALD B. SCHWADRON		
		_	~o Y			PRIMARY EXAMINER GROUP 1866 L.		



6. Claims 40-42,45-47 remain rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention for the reasons elaborated in paragraph 18 of the previous Office Action. Applicants arguments have been considered and deemed not persuasive.

There is no support in the specification as originally filed for the recitation of "essentially free from contaminating Fc" in claims 40 and 45. The specification and original claims 27 and 29 do not recite that the claimed F(ab) are essentially free from contaminating Fc. They recite that the claimed F(ab) produce an electrophoresis wherein no precipitation band against anti-Fc antibodies is seen.

Regarding applicants comments, there is no disclosure in the specification as originally filed that the claimed F(ab) are essentially free from contaminating Fc. The specification discloses that the claimed F(ab) produce an electrophoresis wherein no precipitation band against anti-Fc antibodies is seen. There is no disclosure in the specification as originally filed of the scope of the claimed invention wherein the claimed invention is essentially free from contaminating Fc. Regarding applicants comments about the four-hour digest in Figure 4 of the specification, said preparation is not essentially free from contaminating Fc because it contains detectable levels of Fc. Furthermore, the particular experiment which applicant refers to discloses a particular preparation generated under a particular set of conditions. There is no support in the specification as originally filed of the scope of the claimed invention. There is no written description of the scope of the claimed invention as originally filed.

- 7. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 8. Claims 40-42,45-47 stand rejected under 35 U.S.C. § 103 as being unpatentable over Sullivan et al. in view of Coulter et al. and Smith et al. as evidenced by Stedman's Medical



Serial No. 08/405454 Art Unit 1644


Dictionary (1977) for the reasons elaborated in the previous Office Action. Applicants arguments have been considered and deemed not persuasive.

Regarding the Russell declaration filed 5/4/98, the following comments are made. Coulter et al. teach that F(ab) which neutralizes a large molecular weight protein snake toxin can be made and that said antivenom can work in vivo to neutralize snake toxin (see page 202, third paragraph). Smith et al. teach that Fab fragments can be used to neutralize digoxin (low molecular weight potential toxin)(see Summary). Smith et al. also teaches that relatively rapid clearance of Fab fragments can be used to advantage when the objective is rapid neutralization and clearance of a toxic substance (see page 393, Discussion section) indicating that Smith et al. believed that Fab could be used for the neutralization of toxic substances other than digoxin. Furthermore, Smith et al. indicated that Fab and the intact antibody from which the Fab were derived would be expected to have similar binding properties (see page 393, Discussion section). Thus, the art recognized that when an intact antibody has been shown to have the capability of neutralizing a toxin, that the Fab derived from said antibody will also be able to neutralize said toxin. Furthermore, based on the teachings of Coulter et al. and Smith et al. it appears that use of Fab to neutralize toxin (wherein the intact antibody had already been shown to be capable of neutralizing said toxin) would be equally applicable to large and small toxin molecules. Regarding the Faulstich et al. reference said reference teaches that monoclonal antibody against alpha amatoxin cannot be used to treat alpha amatoxin and that F(ab) obtained from said antibody also cannot be used to treat alpha amatoxin. Thus, the circumstances surrounding treatment of alpha amatoxin poisoning differ from treatment of snake venom because the use of antibody to treat snake venom is well known in the art and Coulter et al. teach that F(ab) antivenin can be made and that said antivenin work in vivo to neutralize snake toxins (see page 202, third paragraph). Regarding comments about Balthasar et al., Balthasar et al. refer to alpha amatoxin, which is a toxin which cannot be treated with antibodies as shown by Faulstich et al. The circumstances surrounding treatment of alpha amatoxin poisoning differ from treatment of snake venom because the use of antibody to treat snake venom is well known in the art and Coulter et al. teach that F(ab) antivenin can be made and that said antivenin work in vivo to neutralize snake toxins (see page 202, third paragraph). Furthermore, Balthasar et al. teach that the use of drug-binding antibodies and antibody fragments for the treatment of drug intoxication is well known. (see Abstract, last sentence). Thus, there are no negative teachings in Faulstich et al. or Balthasar et

Serial No. 08/405454 Art Unit 1644

al, that would suggest that F(ab) antivenin could not be used to treat snake venom poisoning. Regarding various comments in pages 8-12 of the Russell declaration as to why it would be unpredictable as to whether the Fab antivenom of the claimed invention would work in vivo, there is no disclosure in the Russell declaration of any reference which states that Fab fragments could not neutralize toxin wherein the fragments were derived from an antibody that had been previously shown to neutralize the toxin, and based on the teachings of Coulter et al. and Smith et al. it appears that use of Fab to neutralize toxin (wherein the intact antibody had already been shown to be capable of neutralizing said toxin) would be equally applicable to large and small toxin molecules. Regarding comments in the Russell declaration about Coulter et al., the art already recognized that intact antibody against Crotalus snake venom could be used to treat Crotalus snake venom in vivo. The Smith et al. reference indicates that Fab actually have a more favorable distribution in vivo than intact antibody in that Fab can be found in particular anatomical compartments such as the extravascular space wherein intact antibody occurs in smaller concentrations. Regarding comments about Sorkine et al., Sorkine et al. disclose that Fab was successfully used to neutralize toxin in vivo and that "One explanation is the different kinetics of these fragments. The smaller size of Fab results in faster diffusion and a greater volume of distribution". Thus, Sorkine et al. confirm the teachings of Smith et al. that Fab actually have a more favorable distribution in vivo than intact antibody with regards to the neutralization of toxin. Regarding applicants comments about Sorkine et al., Coulter et al. teach that Fab work in vivo to neutralize a snake toxin. Regarding the fact that the toxin and antibody were first mixed before in vivo injection, the art already recognized that the antivenom from which the Fab would have been derived could bind Crotalus venom, and Smith et al. reference indicates that Fab actually have a more favorable distribution in vivo than intact antibody with regards to the neutralization of toxin. Furthermore, Sorkine et al. actually confirm that with regards to Fab that the in vitro mixture of the antibody and toxin prior to administration mirrors the effect seen when Fab and toxin are administered separately in vivo. Regarding applicants comments, antisera against Crotalus toxin which contained antibodies to neutralize said toxin/toxins was already known in the art. Smith et al. teach that F(ab) are less immunogenic than the antibody from which they are derived (see page 395). Smith et al. teaches that,

"Relatively rapid clearance of Fab fragments can be used to advantage when the objective is rapid neutralization and clearance of a toxic substance, and purified sheep digoxin specific Fab



fragments have been utilized clinically for the reversal of advanced digoxin intoxication. This therapeutic approach is based on similar binding properties and the postulated lesser immunogenicity of Fab compared with IgG." (page 393).

9. Claims 45-47 remain rejected under 35 U.S.C. § 103 as being unpatentable over Sullivan et al. in view of Coulter et al. for the reasons elaborated in the previous Office Action. Applicants arguments have been considered and deemed not persuasive.

Regarding applicants arguments as they apply to the instant rejection, the claimed invention under consideration is not drawn to an antivenom. It is drawn to a Fab antibody. Whether or not an antivenom based on the Fab recited in the claims could be used to treat snake bites in vivo is not germane to the claimed invention because the claimed Fab can be used in vitro assays. Coulter et al. teach that: "Fab fragments of IgG have been used in enzyme immunoassay instead of IgG (Kato et al. 1976). EIAs of higher sensitivity have been claimed when Fab enzyme is used instead of IgG enzyme." (page 199, first paragraph).

- 10. The rejection of claims 40-42,45-47 under 35 U.S.C. 102(a) as being anticipated by Sullivan et al. (Veterinary and Human Toxicology) for the reasons elaborated in the previous Office Action is withdrawn in view of the second Russell declaration filed 5/4/98.
- 11. Regarding applicants request for an interview, applicant is invited to call the Examiner and schedule an interview.
- 12. Papers related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Papers should be faxed to Group 1600 at (703) 305-3014.
- 13. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Dr. Ron Schwadron whose telephone number is (703) 308-4680. The examiner can normally be reached Tuesday through Friday from 8:30 to 6:00. The examiner can also be reached on alternative Mondays. A message may be left on the examiners voice mail

Serial No. 08/405454

Art Unit 1644

service. If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Ms Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

RONALD B. SCHWADRON PRIMARY EXAMINER GROUP 1800 (600)

Ron Schwadron, Ph.D.

Primary Examiner

Art Unit 1644

June 23, 1998